Cutting-edge Insights into Liver Fibrosis: Advanced Therapeutic Strategies and Future Perspectives Using Engineered Mesenchymal Stem Cell-derived Exosomes

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Date 2025 Jan 24

PMID 39853531

Authors

Manar A Didamoony

Ayman A Soubh

Lamiaa A Ahmed

Affiliations

Soon will be listed here.

Abstract

Liver fibrosis is still a serious health concern worldwide, and there is increasing interest in mesenchymal stem cells (MSCs) with tremendous potential for treating this disease because of their regenerative and paracrine effects. Recently, many researches have focused on using the released exosomes (EXOs) from stem cells to treat liver fibrosis rather than using parent stem cells themselves. MSC-derived EXOs (MSC-EXOs) have demonstrated favourable outcomes similar to cell treatment in terms of regenerative, immunomodulatory, anti-apoptotic, anti-oxidant, anti-necroptotic, anti-inflammatory and anti-fibrotic actions in several models of liver fibrosis. EXOs are superior to their parent cells in several terms, including lower immunogenicity and risk of tumour formation. However, maintaining the stability and efficacy of EXOs after in vivo transplantation remains a major challenge in their clinical applicability. Therefore, several strategies have been applied in EXOs engineering, such as parental cell modification or modifying EXOs directly to achieve optimum performance of EXOs in treating liver fibrosis. Herein, we discuss the underlying mechanisms of liver fibrosis with an overview of the available therapies, among them EXOs. We also summarise the recent developments in improving the effectiveness of EXOs with the advantages and limitations of these approaches in terms of the upcoming clinical applications.

References

Elbaset M, Mohamed B, Hessin A, Abd El-Rahman S, Esatbeyoglu T, Afifi S . Nrf2/HO-1, NF-κB and PI3K/Akt signalling pathways decipher the therapeutic mechanism of pitavastatin in early phase liver fibrosis in rats. J Cell Mol Med. 2024; 28(3):e18116. PMC: 10844702. DOI: 10.1111/jcmm.18116. View

El-Agroudy N, El-Naga R, El-Razeq R, El-Demerdash E . Forskolin, a hedgehog signalling inhibitor, attenuates carbon tetrachloride-induced liver fibrosis in rats. Br J Pharmacol. 2016; 173(22):3248-3260. PMC: 5071558. DOI: 10.1111/bph.13611. View

Didamoony M, Atwa A, Ahmed L . Modulatory effect of rupatadine on mesenchymal stem cell-derived exosomes in hepatic fibrosis in rats: A potential role for miR-200a. Life Sci. 2023; 324:121710. DOI: 10.1016/j.lfs.2023.121710. View

Yang X, Wang Z, Kai J, Wang F, Jia Y, Wang S . Curcumol attenuates liver sinusoidal endothelial cell angiogenesis via regulating Glis-PROX1-HIF-1α in liver fibrosis. Cell Prolif. 2020; 53(3):e12762. PMC: 7106966. DOI: 10.1111/cpr.12762. View

Ding Y, Luo Q, Que H, Wang N, Gong P, Gu J . Mesenchymal Stem Cell-Derived Exosomes: A Promising Therapeutic Agent for the Treatment of Liver Diseases. Int J Mol Sci. 2022; 23(18). PMC: 9502508. DOI: 10.3390/ijms231810972. View

Wei W, Ao Q, Wang X, Cao Y, Liu Y, Zheng S . Mesenchymal Stem Cell-Derived Exosomes: A Promising Biological Tool in Nanomedicine. Front Pharmacol. 2021; 11:590470. PMC: 7944140. DOI: 10.3389/fphar.2020.590470. View

Yin T, Liu Y, Ji W, Zhuang J, Chen X, Gong B . Engineered mesenchymal stem cell-derived extracellular vesicles: A state-of-the-art multifunctional weapon against Alzheimer's disease. Theranostics. 2023; 13(4):1264-1285. PMC: 10008732. DOI: 10.7150/thno.81860. View

Khanam A, Saleeb P, Kottilil S . Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?. Cells. 2021; 10(5). PMC: 8147843. DOI: 10.3390/cells10051097. View

Matsuda M, Seki E . The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix. Food Chem Toxicol. 2020; 143:111556. PMC: 7484466. DOI: 10.1016/j.fct.2020.111556. View

10.

Wynn T, Ramalingam T . Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012; 18(7):1028-40. PMC: 3405917. DOI: 10.1038/nm.2807. View

11.

Tsukada S, Parsons C, Rippe R . Mechanisms of liver fibrosis. Clin Chim Acta. 2005; 364(1-2):33-60. DOI: 10.1016/j.cca.2005.06.014. View

12.

Sanchez-Valle V, Chavez-Tapia N, Uribe M, Mendez-Sanchez N . Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem. 2012; 19(28):4850-60. DOI: 10.2174/092986712803341520. View

13.

Yang J, Tao H, Hu W, Liu L, Shi K, Deng Z . MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis. Cell Signal. 2014; 26(11):2381-9. DOI: 10.1016/j.cellsig.2014.07.016. View

14.

Didamoony M, Atwa A, Abd El-Haleim E, Ahmed L . Bromelain ameliorates D-galactosamine-induced acute liver injury: role of SIRT1/LKB1/AMPK, GSK3β/Nrf2 and NF-κB p65/TNF-α/caspase-8, -9 signalling pathways. J Pharm Pharmacol. 2022; 74(12):1765-1775. DOI: 10.1093/jpp/rgac071. View

15.

Zhao X, Yu H, Yang Y, Wu W, Chen T, Jia K . Polydatin prevents fructose-induced liver inflammation and lipid deposition through increasing miR-200a to regulate Keap1/Nrf2 pathway. Redox Biol. 2018; 18:124-137. PMC: 6068203. DOI: 10.1016/j.redox.2018.07.002. View

16.

Goodman Z . Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007; 47(4):598-607. DOI: 10.1016/j.jhep.2007.07.006. View

17.

Czaja A . Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014; 20(10):2515-32. PMC: 3949261. DOI: 10.3748/wjg.v20.i10.2515. View

18.

Sharma N, Sistla R, Andugulapati S . Yohimbine ameliorates liver inflammation and fibrosis by regulating oxidative stress and Wnt/β-catenin pathway. Phytomedicine. 2023; 123:155182. DOI: 10.1016/j.phymed.2023.155182. View

19.

Dutta S, Chakraborty A, Dey P, Kar P, Guha P, Sen S . Amelioration of CCl4 induced liver injury in swiss albino mice by antioxidant rich leaf extract of Croton bonplandianus Baill. PLoS One. 2018; 13(4):e0196411. PMC: 5927454. DOI: 10.1371/journal.pone.0196411. View

20.

Karantonis H, Gribilas G, Stamoulis I, Giaginis C, Spiliopoulou C, Kouraklis G . Platelet-activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis. Dig Dis Sci. 2009; 55(2):276-84. DOI: 10.1007/s10620-009-0745-0. View